Temel Kavramlar
Tardive dyskinesia is a chronic and progressive movement disorder caused by long-term use of antipsychotic medications, which can significantly impact patients' quality of life and daily functioning.
Özet
The content provides a comprehensive overview of tardive dyskinesia (TD), a movement disorder associated with long-term use of antipsychotic medications.
Key highlights:
- TD is believed to result from disruption of dopaminergic, GABAergic, and other neurotransmitter systems in the brain, leading to motor abnormalities.
- Patients with TD can exhibit a wide range of involuntary movements, including facial twitches, lip smacking, tongue protrusion, and limb movements.
- While preventing TD by using the lowest effective dose of antipsychotics or switching to a lower-potency medication is the best strategy, various treatment options are available to manage TD symptoms, including VMAT-2 inhibitors, clonazepam, and deep brain stimulation.
- Diagnosing TD can be challenging due to the overlap of symptoms with other neurological disorders, requiring a thorough differential diagnosis.
- TD poses a significant burden on patients' quality of life, daily functioning, and emotional well-being, as well as a financial burden on the healthcare system.
İstatistikler
"TD most commonly develops in patients with schizophrenia and related conditions following long-term use of dopamine antagonist antipsychotic medications, and older age, female sex, prior brain injury, and genetic variants such as PIP5K2A can also influence TD risk."
"Patients with TD incur significantly higher healthcare utilization, with a 26% increase in total costs compared with people who do not have TD."
Alıntılar
"TD is chronic and progressive and can cause significant patient burden and disability."
"The Abnormal Involuntary Movement Scale is a widely used screening tool that evaluates abnormal motor function across various regions of the body."
"The vesicular monoamine transport type 2 (VMAT-2) inhibitors valbenazine and deutetrabenazine have been approved by the US Food and Drug Administration to treat TD."